ESMO Advanced Course on Biomarkers for Precision Medicine

Programme

ESMO VIRTUAL ADVANCED COURSE

4-5 SEPTEMBER 2020

Co-Chairs
Albrecht Stenzinger, Germany
Daniel S. W. Tan, Singapore
ESMO VIRTUAL ADVANCED COURSE PROGRAMME
ON BIOMARKERS FOR PRECISION MEDICINE
4-5 September 2020

CO-CHAIRS: Albrecht Stenzinger, Germany
              Daniel S. W. Tan, Singapore

SPEAKERS: Catherine Alix-Panabières, France
          Leticia De Mattos-Arruda, Spain
          Florent Ginhoux, Singapore
          Antoine Italiano, France
          Tony K. H. Lim, Singapore
          Serena Nik-Zainal, United Kingdom
          Emanuela Romano, France
          Tira J. Y. Tan, Singapore
          Joe P. S. Yeong, Singapore
          Alex H. Wagner, United States

LEARNING OBJECTIVES

- An increasing number of therapeutics that require biomarkers testing are available for clinical use or are in advanced phase of clinical development
- Different technologies can be used for biomarker testing depending on the nature of the biomarker and the availability of biological samples
- The increasing use of large panels for comprehensive genomic profiling raises issues on data interpretation that require a multidisciplinary approach
- Monitoring the molecular evolution of the disease might allow the identification of resistance mechanisms and the development of more effective therapeutic strategies
- The identification of germline variants requires the activation of genetic counselling programs for patients and their families

All timings are to be considered GMT+8

ACCREDITATION
The programme of this event has been accredited with 7 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS
This event is supported by an unrestricted educational grant from

Lilly Oncology

MSD
Friday, 4 September 2020

15:00-15:05 Welcome and introduction

5’ Welcome and Learning Objectives Introduction
Albrecht Stenzinger, DE and Daniel S. W. Tan, SG

15:05-16:20 Session 1 – Genomic alterations

20’ Overview and assays commonly used, Tony K. H. Lim, SG
20’ Clinical Variant Interpretation, Antoine Italiano, FR
20’ Harmonizing variant interpretation, Alex H. Wagner, US
15’ Discussion

16:20-16:30 Break

16:30-17:30 Session 2 – Gene fusion

20’ Technical aspects, Albrecht Stenzinger, DE
20’ Clinics (NTRK, RET, ROS1, FGFR2, NRG1, etc…), Daniel S. W. Tan, SG
20’ Discussion

17:30-18:30 Session 3 – Homologous Repair Deficiency

20’ Technical aspects and definition, Serena Nik-Zainal, UK
20’ Clinics (ovarian, mPCA, PDAC,…), Tira J. Y. Tan, SG
20’ Discussion

Saturday, 5 September 2020

15:00-16:00 Session 4 – Liquid biopsy

20’ Technical aspects, Catherine Alix-Panabières, FR
20’ Clinics (trials most importantly), Leticia De Mattos-Arruda, ES
20’ Discussion

16:00-17:00 Session 5 – Immuno-oncology biomarkers (IO)

20’ Current biomarkers in clinical use, Emanuela Romano, FR
10’ In development: Tissue multiplexed biomarkers, Joe P. S. Yeong, SG
10’ In development: Immune-monitoring and single cell, Florent Ginhoux, SG
20’ Discussion

17:00-17:10 Break
17:10-18:30  Workshop sessions

Workshop 1  Interactive Molecular Tumour Board
Albrecht Stenzinger, DE and Daniel S. W. Tan, SG
15’ Introduction based on clinical cases presented by speakers
25’ Discussion

Workshop 2  Interactive Practical Session
Albrecht Stenzinger, DE and Daniel S. W. Tan, SG
40’ Challenges in assay interpretation with discussion after each question

18:30-18:40  Synthesis and wrap-up

ORGANISATION AND CONTACTS
ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org